Article
Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis.
Annals of the American Thoracic Society - 1 Mar 2018
Ren Clement L, Morgan Rebecca L, Oermann Christopher, Resnick Helaine E, Brady Cynthia, Campbell Annette, DeNagel Richard, Guill Margaret, Hoag Jeffrey, Lipton Andrew, Newton Thomas, Peters Stacy, Willey-Courand Donna Beth, Naureckas Edward T
Abstract excerpt
RATIONALE: Cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulators are a new class of medications targeting the underlying defect in CF. Ivacaftor (IVA) and IVA combined with lumacaftor (LUM; IVA/LUM) have been approved by the U.S. Food and Drug Administration (FDA) for use in patients with CF. However, the FDA label for these medications encompasses patient groups that were not studied as part...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.